AzTrials
AzTrials

Diabetes Mellitus, Type 2NCT04950283

MR-based Characterization of Bone Marrow in Its Relevance to Skeletal Disease in Patients With Diabetes

An observational study of Diabetes Mellitus, Type 2 and Osteoporosis, run by University Hospital Tuebingen at 1 site in Germany.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

For a long time, no direct connection was seen between the two common diseases diabetes mellitus and osteoporosis. However, as more and more younger people are affected by obesity, develop type 2 diabetes mellitus and suffer osteoporotic fractures, the question of a connection between these clinical pictures has now… Read more about this study

Who is it for?
Ages 25 to 75 yearsHealthy volunteers can take part
What is being tested?
magnetic resonance examination, anthropometric and metabolic characterization
Type of treatment
Pill or oral medicine
How many people
85 participants
Where
1 siteGermany
Study dates
7 Jul 2021to 31 Dec 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 75 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: community sample

Who may be able to join

  • Body mass index between 18,5 and 35 kg/m²
  • Age between 25 and 75 years
  • Ability to understand and follow study-related instructions
  • Consent to information in case of unexpected detected pathological findings

Who cannot join

  • contraindications for magnetic resonance imaging (metal in or on the body, e.g. pacemaker)
  • pregnancy
  • people with limited thermal sensors or increased sensitivity to heating
  • Persons in whom circulatory disease cannot be excluded after questioning
  • Individuals who report a hearing disorder or increased sensitivity to loud sounds
  • Claustrophobia
Show all 13Show fewer
  • subjects incapable of giving consent are excluded
  • acute illness or infection within the last 4 weeks
  • Conditions that, in the judgment of an investigator, jeopardize the success of the study or indicate that the subject is at risk of harm
  • type 1 diabetes
  • Patients with type 2 diabetes and pharmacologic therapy for diabetes outside of metformin and DPP-IV inhibitors
  • HbA1c > 10,0 %
  • duration of diabetes >= 2 years

Trial locations and contacts

1 site in 1 country.

Germany1 site
  • University Hospital

    Tübingen, 72076

Other trials in Germany

About this study

Official title: MR-basierte Charakterisierung Des Knochenmarks in Seiner Bedeutung für Skeletterkrankungen Von Patienten Mit Diabetes

For a long time, no direct connection was seen between the two common diseases diabetes mellitus and osteoporosis. However, as more and more younger people are affected by obesity, develop type 2 diabetes mellitus and suffer osteoporotic fractures, the question of a connection between these clinical pictures has now arisen.

Modern magnetic resonance imaging and spectroscopy techniques allow detailed and non-invasive characterization of bone marrow in different body regions.

Read more

Low body weight (BMI<20kg/m²) has been shown to be associated with decreased bone density, while obesity has long been associated with high cortical bone mass - the idea of bone health. It has now been proven that obesity also has a negative effect on bone structure. Here, it is not only BMI that is crucial, but also the localization of fat tissue in the body. Visceral fat has a directly damaging effect on bone microarchitecture through dysregulated production and release of cytokines and adipokines. Thus, it has been shown that both type 1 and type 2 diabetic patients have a decreased rate of bone remodeling and very obese patients with type 2 diabetes have an increased risk of fracture. It must be concluded that body weight, or BMI, cannot be the sole measure for estimating bone health. Thus, type 2 diabetes shows reduced bone remodeling with normal or slightly increased bone density, but inferior stability. This means that type 2 diabetes is associated with an increased risk of osteoporotic fracture, even when bone density measurements are unremarkable. Loss of trabecular bone structure in red (hematopoietic) bone marrow is also characterized by increasing infiltration of the bone marrow space with fat cells (bone marrow adipose tissue). In contrast, the yellow bone marrow, which is mainly present in the diaphysis of tabular bones, has particularly large amounts of fat incorporated into the reticulum cells.

For a long time, only the role of "placeholder" was attributed to these fat cells, but it has been shown that they interact with other cells via the production of autocrine, paracrine and endocrine hormones and cytokines, or adipokines, and are thus related to the metabolic state of the entire body. A basic assumption here is that the amount of unsaturated fatty acids in the adipose bone marrow is an important and functional marker for different types of adipocytes. It has been shown that 3 individuals with poorer insulin sensitivity have more unsaturated fatty acids in yellow bone marrow.

Thus, the concept of different types of adipocytes in the bone marrow, with their inherent different fatty acid composition could serve to reconcile the at first glance counterintuitive physiological regulation of bone marrow fat and its response to metabolic perturbations.

In order to show whether and how the composition of the yellow (unsaturated fatty acids) and red (bone marrow adipose tissue) bone marrow differs in healthy individuals, individuals with impaired insulin sensitivity in different age groups and patients with type 2 diabetes, and whether this can be used to detect early changes in the bone matrix with regard to bone density, the proportion of bone marrow adipose tissue in the red bone marrow at different locations in the skeleton will be quantified by means of chemical-shift-selective MRI sequences as well as the composition of bone marrow fat in the yellow bone marrow with regard to the proportions of monounsaturated and polyunsaturated fatty acids by means of volume-selective MRS.

A total of 96 healthy volunteers (48 each male and female) aged 25 to 75 years and with body mass index between 18.5 and 35 kg/m² will be included. In addition, 24 patients (12female/12male) with type 2 diabetes will be recruited.

After magnetic resonance examination, anthropometric and metabolic characterization (oral glucose tolerance test) will take place.

Being tested
magnetic resonance examination, anthropometric and metabolic characterization
Medical subject headings
Diabetes Mellitus, Type 2, Osteoporosis, Insulin Resistance

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • magnetic resonance examination, anthropometric and metabolic characterizationDiagnostic test

    Participants undergo a magnetic resonance examination, anthropometric characterization and metabolic characterization via oral glucose tolerance test.

Study groups in NCT04950283
Study groupRoleWhat they receive
Magnetic resonance examination and anthropometric, metabolic characterizationNot described
Receives: Diagnostic Test: magnetic resonance examination, anthropometric and metabolic characterization

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. monounsaturated and polyunsaturated fatty acids in the yellow bone marrow

    The composition of the lipids in the yellow bone marrow (monounsaturated and polyunsaturated fatty acids) will be determined by volume selective Proton magnetic resonance spectroscopy

    Measured: about 10 minutes

  2. Fat content in the red bone marrow of the vertebral bodies and femura

    Proton density fat fraction will be determined by multi-echo Dixon-Imaging

    Measured: 120 seconds

  3. Fat and water selective tomograms from shoulders to knees

    Fat and water selective tomograms from shoulders to knees will be created by chemical-shift-selective recording technique

    Measured: 68 seconds

  4. Insulin sensitivity

    Insulin sensitivity will be examined by oral glucose tolerance test

    Measured: Sample collection will be from 0 to 120 minutes (every 30 minutes)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jul 2021
  2. Study start7 Jul 2021
  3. Primary completion25 Apr 2023
  4. Study completion31 Dec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
85 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04950283
Sponsor's protocol ID
Knoma
Status last verified
May 2024
First submitted
23 Jun 2021
Last updated
14 May 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetes Mellitus, Type 2 and Osteoporosis, run by University Hospital Tuebingen at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 14 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

monounsaturated and polyunsaturated fatty acids in the yellow bone marrow (time frame: about 10 minutes). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in